# Single-centre, Randomised, Double-blind, Placebo-controlled, Four-way Crossover Clinical Study to Investigate Safety and Tolerability and Pharmacokinetics of Single Doses of CM3.1-AC100 in Patients With Type 2 Diabetes

> **NCT01196728** · PHASE1 · COMPLETED · sponsor: **CellMed AG, a subsidiary of BTG plc.** · enrollment: 16 (estimated)

## Conditions studied

- Type II Diabetes Mellitus

## Interventions

- **DRUG:** CM3.1-AC100

## Key facts

- **NCT ID:** NCT01196728
- **Lead sponsor:** CellMed AG, a subsidiary of BTG plc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2010-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01196728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01196728, "Single-centre, Randomised, Double-blind, Placebo-controlled, Four-way Crossover Clinical Study to Investigate Safety and Tolerability and Pharmacokinetics of Single Doses of CM3.1-AC100 in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01196728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*